Raje, Noopur <br/><br/>
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.  [electronic resource] 

 -  Blood  Aug 2005 
 - 1042-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2005-01-0320  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis<br/>Cell Adhesion<br/>Coculture Techniques<br/>Cyclin-Dependent Kinases--antagonists & inhibitors<br/>DNA-Binding Proteins--metabolism<br/>Down-Regulation--drug effects<br/>Drug Synergism<br/>Humans<br/>Interleukin-6--genetics<br/>Multiple Myeloma--drug therapy<br/>Myeloid Cell Leukemia Sequence 1 Protein<br/>Neoplasm Proteins--drug effects<br/>Proto-Oncogene Proteins c-bcl-2--drug effects<br/>Purines--pharmacology<br/>Roscovitine<br/>STAT3 Transcription Factor<br/>Stromal Cells--cytology<br/>Trans-Activators--metabolism<br/>Transcription, Genetic--drug effects<br/>Tumor Cells, Cultured